KYNB/ 07/06/2026 · 5:44 PM Kyntra Bio Scores First Analyst Coverage: Oppenheimer Initiates Outperform with $35 Target Kyntra Bio gains analyst support as its cancer drugs advance, with key Phase 2 data expected to drive future growth.
